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Abstract Phospholipase activity is elevated in dividing cells. In 
response to growth factor stimulation, phospholipase C-y (PLC- 
3') binds to activated tyrosine kinase receptors via SH2 binding 
domains, resulting in phosphorylation of PLC-y and activation 
of its enzyme activity. These observations uggest hat PLC-y 
participates in the signal transduction pathway employed by 
growth factors to promote mitogenesis. Consistent with this hy- 
pothesis, microinjection of purified bovine PLC-y into quiescent 
fibroblasts has been previously reported to initiate a mitogenic 
response [Smith et al. (1989) Proc. Natl. Acad. Sci. 86, 3659]. We 
have reproduced this result using recombinant rat PLC-y protein. 
Surprisingly, however, a catalytically inactive mutant of PLC-% 
H335Q, also elicited a full mitogenic response. The capacity to 
induce mitogenesis by microinjection of PLC-y was mapped to 
the 'Z' domain of the protein, which contains PLC-T's SH2 and 
SH3 motifs. Inactivation of t~e phosphorylated tyrosine binding 
properties of both SH2 domains had no effect on the mitogenic 
activity of the Z-domain peptide. However, deletion of the SH3 
domain resulted in a complete loss of activity. These results 
suggest that PLC-y's mitogenic properties do not require the 
enzyme's phospholipase activity, but are instead mediated by a 
novel pathway for mitogenic stimulation which is dependent upon 
an intact SH3 domain. 
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1. Introduction 
Phospholipase C (PLC) generates two second messengers 
from the hydrolysis of phosphotidylinositol 4,5bisphosphate: 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). 
DAG is an activator of protein kinase C, and IP 3 has been 
shown to regulate intracellular calcium (for reviews, see [2,3]). 
To date, 9 isoforms of mammalian PLC enzymes have been 
described, all of which generate the same second messengers. 
Activation of these enzymes is observed in a variety of signal 
transduction pathways, wherein different isozymes of PLC are 
activated by different growth factors. For example, PLC-fl is 
activated by the transforming ~ subunit of the Gq protein [4,5], 
and PLC-y forms 1 and 2 are activated by the tyrosine kinase 
growth factor receptors of EGF and PDGF [6-12]. Only the y 
forms of PLC contain SH2 and SH3 domains. The SH2 do- 
mains mediate a physical association between PLC-F and 
phosphorylated tyrosines on the activated tyrosine kinase re- 
ceptors. SH3 domains bind to poly-proline sequences, and at 
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least one protein which specifically associates with PLC-z 
through its SH3 domain, dynamin, has been identified [13,14]. 
The region of PLC-y which contains the SH2 and SH3 do- 
mains has been designated the 'Z' region [15]. This region of 
the molecule resides between the C-terminal catalytic regions, 
denoted X and Y (Fig. l a). The Z domain bears striking simi- 
larity to the oncogenic adapter protein, Nck [16-19]. Nck con- 
tains two SH2 domains and three SH3 domains, at least one 
of which shares a common antigenic epitope with PLC-z SH3. 
The degree of sequence homology suggests the possibility that 
PLC-y, like other proteins involved in signal transduction (e.g. 
GAP), can act both as an enzyme and an adapter protein during 
signal transduction. 
The data suggesting that overexpression of PLC-y is suffi- 
cient to elicit a mitogenic response in mammalian cells is incon- 
clusive. Microinjection of purified bovine PLC-z has been 
shown to activate S-phase DNA synthesis in serum starved 
N1H 3T3 cells [1]. In addition, rat cells transfected with Z-like 
peptides expressed under the CMV promoter exhibited short- 
ened cell cycles and increased DNA synthesis [20]. In contrast, 
however, stable overexpression of full-length PLC-y using 
DNA vectors causes no phenotypic changes in 3T3 fibroblasts 
[21]. The disparity in results between these systems may reflect 
differences in PLC-y concentrations, processing, or localiza- 
tion. 
In the current study, we have identified the domains of PLC- 
y which are necessary for the mitogenic activity resulting from 
microinjection of recombinant enzyme into quiescent 3T3 fi- 
broblasts. This work demonstrates that while the SH3 domain 
of PLC-y is necessary to initiate a mitogenic response, neither 
its catalytic activity nor its SH2 domains are required. 
2. Materials and methods 
2.1. Construction of expression plasmids 
Cloning of recombinant rat PLC-), containing a three amino acid 
epitope tag (EEF) at the carboxy-terminus has been previously de- 
scribed [22]. All subsequent peptides were constructed by PCR amplifi- 
cation of rat PLC-y or human PLC-z sequences. All PCR fragments 
were verified by DNA sequencing (USB; Sequenase). Construction of 
mutant PLC-), H335Q was accomplished by two step PCR amplifica- 
tion of mutant DNA oligomers containing a transversion from T to A 
at nucleic acid position 1036 [23]. Oligonucleotides u ed to create the 
mutant were purchased from Midland Reagents, TX, and were as 
follows: 
5'-CTTC CTCGCAAAATACGTATC 
5'-GATACGTATTTTGCGAGGAAG 
Oligomers homologous to flanking sites in the vector and PLC se- 
quences were used for outside amplification. The 980 bp PCR product 
was subcloned into the PLC expression construct using unique EcoR1 
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and NcoI sites, and was sequenced toconfirm that only one nucleotide 
was mutated. 
The rat PLC Z domain and human PLC Z domains are virtually 
identical. Only 9 amino acid differences exist between the two proteins, 
and all of these substitutions are conservative. Human Z-protein frag- 
ment was made by digestion of a partial human PLC-y cDNA clone 
with AvrlI and BgllI. The 1071 bp fragment was cloned into the expres- 
sion vector, T5T, using unique sites [24]. DNA linkers were used to put 
the EEF tag in frame at the carboxy-terminus: 
5 ' -CTAGGGGAAGAGTTCTAGTA -3  ' 
3 ' - CCCTTCTCAAGATCATTCGA -5 '  
and to add a methionine to the amino-terminus: 
5'  -AATTCGGATCCATTGGAGGATGATTAAATGAA 3 ' 
3 ' - GCCTAGGGTAACCTCCTACTAATTTACTTCTTCTAG -5  ' 
Z-protein includes PLC  amino acids 516-869. Mutant Z-proteins 
were constructed by PCR using wild type Z-protein in T5T as a tem- 
plate. Point mutants in each individual SH2 homology were constructed 
separately using two step PCR amplification, then a double mutant was 
created by ligation of mutant fragments using the internal KpnI site. 
The final double Z(SH2-/-) mutant contained two mutations, R ---> K 
at R s86 and R 694. Fragment inserts were verifed by sequencing. Primers 
overlapping the R586K mutation were: 
5 ' -TCCTCGTGAAAGAGAGTGAGACCTTCG 
5 ' -CACTCTCTTTCACGAGGAAGGAGCCGTC 
Primers for the R694K mutation were: 
5 '  - TCCTGGTGAAGAAGCGGAATGAACC CAAC 
5 ' -TCCGCTTCTTCACCAGGAAGGCCCCATC 
Deletion of the SH3 moiety was accomplished by overlap PCR span- 
ning sequences surrounding amino acids 798-846. DNA oligomers used 
to create this deletion were: 
5 ' -GCAGTCAAAGAAGAGATGGTCA_ACCCCG 
5 ' - CATCTCTTCTTTGACTGCACACTTGAAAG 
To construct the previously described GST-PLC-y SH3 fusion pro- 
tein [25], a PCR product including PLC amino acids 796-851 was made 
in-frame with the BamHI and EcoRI sites in pGEX-2T. The oligos used 
for this amplification were: 
5'  - GCTGGATC CGTCAAAGCCCTCTTTGAC 
5 ' -GCAGGAATTCAGTTGACCATCTCTTCCAC 
2.2. Purification of recombinant proteins 
Recombinant protein was purified from E. coli strain BL21 contain- 
ing the appropriate expression constructs. Expression and purification 
of the proteins was performed essentially as previously described [22]. 
Briefly, expression was induced by IPTG (0.1 mM) for 2~, h at 25 or 
37°C. Cells were centrifuged and soluble PLC-Z protein was isolated 
with the immobilized YL1/2 monoclonal antibody, eluted with 5 mM 
AspPhe dipeptide (Sigma) and concentrated, if necessary. Expression 
of the GST-PLC-?" SH3 fusion was performed as previously described 
[26]. Mutant Val-12 Ras was obtained from J. Gibbs (Merck). Protein 
concentrations were determined by Bradford reagent (Biorad). As a 
negative control, comparable volumes of extracts made from mock- 
transfected bacteria were also eluted from the antibody column. For 
injection, these blank lysates were normalized to PLC-),-containing 
fractions by bacterial volume. Final purified protein fractions were 
analyzed on SDS-PAGE by silver staining with a SilverExpress (Novex) 
development system to assess protein purity. The identity of the purified 
proteins were verified by Western blotting with the appropriate anti- 
sera. Samples were prepared for microinjection by dilution to the final 
concentration in 0.2 M KC1 or phosphate-buffered saline (PBS). Partic- 
ulates were cleared from the sample immediately prior to injection by 
centrifugation at 15,000 × g for 10 min at 4°C. 
2.3. Determination of lipase activity 
PLC-y activity was tested on sonicated lipid vesicles consisting of 
90% dimyristoyl-phosphatidylmethanol (DMPM; Avanti) and 10% 
[3H]phosphatidylinositol-4,5-bisphosphate (PIP2, 2/zCi/mmol; NEN). 
Reactions containing 0.3 mM total lipid in 50 mM Tris, pH 8, and 0.1 
mM CaCI2 were run at room temperature and terminated by addition 
of an equal volume of 200 mM CaC12 in 1 M HC1. Precipitated vesicles 
were collected on filter plates (Millipore; 96-well hydrophobic Multi- 
screen DP plates) and inositol-trisphosphate in the flow-through was 
quantitated by liquid scintillation counting. 
2.4. Microinjection of cells 
Mouse fibroblast, NIH 3T3 cells (subline obtained from D. Stacy) 
were grown in 10% CS, 90% DMEM high glucose (Mediatech, Wash- 
ington, DC), 0.1% pen/strep (Gibco, USA). To prepare cells for micro- 
injection, cells were plated at half-confluence on 175 mm Eppendorf 
CELLocate gridded coverslips. After reaching confluence (usually 
1 day after seeding), cells were growth arrested in media containing 
0.5% serum for 2448 h. Cells were injected in the cytoplasm with an 
AIS Zeiss automatic microinjector. Approximately 100-125 cells within 
a 3 x 3 grid were injected at a partial pressure of 65 psi. DNA synthesis 
was measured using the Cell Proliferation Kit (Amersham) between 
8 and 20 h post-injection. Briefly, cells were incubated in fresh media 
containing 0.5% serum and 40 pM 5-bromo-2'-deoxyuridine (BrdU) 
and 4/.tM 5-fluro-2'-deoxyuridine. At approximately 20 h post-injec- 
tion, unincorporated BrdU was washed from the cytoplasm and nuclear 
BrdU incorporation was measured by immunostaining. To show that 
the incorporation of BrdU reflected S-phase synthesis, DNA labeling 
was shown to occur only between 8-16 h post-injection (data not 
shown). Injected cells were located both by markers on the coverslips 
and by re-examination the Zeiss microinjector. Injections were mon- 
itored in two ways: by parallel co-injections of cells with FITC-dextran 
(MW 10,000; Molecular Probes, OR), or by immunostaining of parallel 
injections. PLC-),, Z-proteins, and GST fusion protein were recognized 
by anti-PLC antisera (Santa Cruz). To visualize cytoplasmic protein, 
cells were fixed in 0.5% paraformaldehyde for 45 min, then further 
solubilized in 0.1% Triton X-100 for 10 min. To block non-specific 
binding, cells were preincubated in PBS containing 1% BSA (Sigma). 
Samples were then incubated for 1 h at room temperature in antibody 
at a concentration of 2/zg/ml. Antibody was identified by binding to 
FITC-conjugated sheep anti-mouse antisera (Molecular Probes). All 
incubations were washed 3 times with PBS at room temperature b fore 
proceeding to the next step. Using these methods, approximately 70- 
90% of cells were successfully injected. 
3. Results and discussion 
Recombinant rat PLC-),I (rPLC-z) containing a three amino 
acid epitope tag (EEF) at the carboxy-terminus (Fig. l a) was 
expressed and purified. A silver stained gel of purified recombi- 
nant rPLC-y is shown in Fig. lb (lanes 7 and 8). A shorter form 
of recombinant PLC-z1 co-purified with both wild type and 
mutant protein. This smaller fragment contains the carboxy- 
terminus of PLC-y, and was a minor component of the prepa- 
ration. As previously reported for the purified bovine enzyme, 
rPLC-y induces a mitogenic response when microinjected into 
quiescent 3T3 fibroblasts (Fig. 2a). Mitogenic activity was mon- 
itored by immunostaining of BrdU incorporation into newly 
synthesized DNA,  and appears as blue-black staining of the 
nucleus. 
Because our recombinant protein was made in E. coli and 
injected into serum starved cells, it is likely that the mitogenic 
effect was mediated by unphosphorylated PLC-y. Other labo- 
ratories have proposed that tyrosine phosphorylation of PLC-y 
is required for activation of the enzyme and subsequent mito- 
genic stimulation (e.g. [5-7]). However, our recombinant pro- 
tein was both enzymatically active and capable of inducing 
mitogenesis. Moreover, a direct comparison between our re- 
combinant PLC-y and PLC-y purified from bovine brain 
showed no difference in specific activity (Huber, data not 
shown), suggesting that lipase activity of our unphosphorylated 
protein was equivalent that of consitutive ndogenous enzyme. 
To determine the role of the catalytic activity of rPLC-z in 
eliciting a mitogenic response, an active-site mutant with re- 
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Fig. 1. Sequence and analysis of PLC-yl proteins. (a) Schematic diagram of PLC-71 proteins. Cloning strategies are described insection 2. (b) Silver 
stain SDS-PAGE of purified protein used for microinjection studies. Markers shown are prestained, MW in kDa from the top: 170, 116.3, 94, 67, 
55.6, 43, 39.2, 30, 26.6, 20.1, 14.4. Sample identification and predicted molecular weight are as follows: lane 1, Z-protein, 41.5 kDa; 2, Z(SH2-/-) 
41.5 kDa; 3, Z (SH3-), 35.7 kDa; 4, mock-transfected bacterial lysate purified over the antibody column, normalized for bacterial volume; 
5, GST-SH3 fusion, 32.8 kDa; 6, GST, 26.0 kDa; 7, WT rat PLC-y 149 kDa, approx. 60 kDa; 8, H335Q mutant rat PLC-y 149 kDa, approx. 60 
kDa. The truncated, approximately 60 kDa fragment present in lanes 7 and 8 was determined by Western analysis to contain the carboxy-terminus 
of the recombinant PLC protein. (c) Enzymatic activity of recombinant rPLC-y 1. Recombinant enzyme was purified and assayed for lipase activity 
as described in section 2. ~, wild type PLC-yl; ©, H335Q mutant; <>, elution buffer. 
duced lipase activity was generated. A point mutant in the 
X-catalytic domain of rPLC (His335---~ Gln) was reported to be 
inactive when overexpressed in mammallian cells [27]. A recom- 
binant version of this mutant protein was constructed and 
tested for lipase activity. As predicted, the mutant rPLC-y 
(H335Q) exhibited less than 10% of the enzymatic activity of 
wild type rPLC (Fig. lc). Surprisingly, microinjection of this 
mutant rPLC-y (H335Q) elicited a mitogenic response compa- 
rable to that of wild type rPLC- 7 (Fig. 2b). Two-fold dilution 
of either protein resulted in the total loss of mitogenic activity. 
As expected, microinjection of a 'null' extract made from non- 
expressing bacterial ysates did not induce mitogenesis (Fig. 
2d). The response of the microinjected cells to PLC proteins 
was morphologically distinct from that of cells injected with 
oncogenic Ras. Cells injected with Ras exhibited both DNA 
synthesis and rounding, as previously described [28]. Cells in- 
jected with rPLC-y were stimulated to synthesize DNA in a 
time-dependent fashion, like Ras-injected cells, but were not 
grossly altered in shape compared to uninjected cells. 
The mitogenic activity of the mutated, lipase-deficient rPLC- 
9" (H335Q) suggests that a property other than the enzymatic 
activity of this enzyme is responsible for the activation of DNA 
synthesis in quiescent fibroblasts. To map the regions of PLC-~" 
necessary for mitogenic activity, a number of recombinant 
PLC-y fragments containing the Z-domain (PLC-y amino acids 
516-869) were expressed in E. coli and purified (Fig. la and b.) 
Fig. 3a~c shows a titration series of microinjected Z-protein 
into serum starved cells. At concentrations of 240/tg/ml and 
120/~g/ml, this molecule was sufficient o induce DNA synthe- 
sis. Normalizing for molecular weight, the Z-protein was 
roughly equipotent to full-length rPLC-z in eliciting a mito- 
genic response upon microinjection i to quiescent 3T3 fibro- 
blasts, suggesting that the Z-domain is responsible for the 
mitogenic activity of full length PLC-y. 
To further map the regions of this protein necessary to elicit 
DNA synthesis, two SH-domain mutants of the Z-protein were 
generated. The integrity of the proteins' SH2 and SH3 domains 
was assayed by binding to a phosphotyrosine-containing SH2-
binding peptide derived from the EGFR protein (EpYLIP) [29] 
and to an SH3-binding peptide derived from dynamin 
(SPTPQRRAPAVPPARPGS, P2 peptide) [13]. The first mu- 
tated Z-protein, designated Z(SH2-/-), contains point mutants 
(Arg---~Lys) in the highly conserved FLVR amino acid se- 
quences of the two SH2 domains. As predicted [30], this double 
point mutant was incapable of binding to the immobilized SH2- 
binding peptide, but did bind to the SH3-binding peptide [13]. 
The other mutated Z-protein, designated Z(SH3-), contained 
a deletion of amino acids 798-846, eliminating the SH3 domain 
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Fig, 2. Microinjection of full length recombinant PLC-yl into quiescent 3T3 fibroblasts. BrdU incorporation i to the nucleus was determined by 
immunostaining as described in section 2. (a) Recombinant rat PLC-y, 150/2g/ml. (b) H335Q rPLC-),, mutant injected, 106 ¢tg/ml. (c) Val-12 H-Ras 
injected, 2.2 mg/ml. (d) Blank lysate injected. (e) 10% serum. (f) 0.5% serum. 
[31]. This mutant protein did not bind to the dynamin SH3- 
binding peptide but did bind to the phosphotyrosine-containing 
peptide, Results from the binding studies are summarized in 
Table 1. 
Microinjection studies were performed with these mutant 
proteins to assess their ability to induce mitogenesis. The 
Z(SH2- / - )  protein, which was unable to bind to the pY pep- 
tide, was fully capable of inducing DNA synthesis in serum 
starved cells at concentrations similar to wild type Z-protein 
Table 1 
Summary of microinjection and peptide binding results 
Protein Enzyme Binds Binds Mitogenic 
activity E(pY)LIP dynamin 
rat PLC-7 1 + + + + 
rat PLC- 7 1 - + + + 
H335Q 
Z-protein NA + + + 
Z (SH2-/-) NA - + + 
Z (SH3-) NA + - - 
GST-SH3 NA NA + - 
Val-12 ras NA NA NA + + + 
NA, not applicable. Mitogenesis key: +++, 50-70% of injected cells 
positive; ++, 20-40% of injected cells positive; +, 10-15% of injected 
cells positive. Binding key: +, > 50% bound to peptide resin; -,  < 5% 
bound to peptide resin. Enzyme activity key: +, specific activity of wild 
type recombinant enzyme; -,  < 10% specific activity relative to wild 
type. 
(Fig. 3d f). Thus, intact SH2 domains were not required for 
mitogenesis. Deletion of the SH3 domain, however, resulted in 
a complete loss of mitogenic activity. Injections of Z(SH3-)  at 
concentrations ranging from 536/lg/ml to 107/lg/ml showed no 
stimulation of DNA synthesis (Fig. 3g-h). Successful microin- 
jection of protein was verified by immunostaining of parallel 
injections with anti-PLC antisera (in section 2, data not shown). 
The results from the previous experiment demonstrate hat 
the SH3 domain was necessary for PLC-7 Z-protein induced 
mitogenesis n quiescent 3T3 fibroblasts. To assess whether this 
domain was sufficient o induce mitogenesis, we microinjected 
a GST-PLC- 7 SH3 fusion protein (PLC-~' amino acids 796- 
851) into quiescent 3T3 fibroblasts. Although this fusion pro- 
tein was sufficient to bind to the dynamin P2 peptide, it was not 
able to induce DNA synthesis in our assay (Table 1). These 
results demonstrate that the PLC- 7 Z-protein is not by itself 
sufficient o initiate a mitogenic response. 
SH3 domains can play either positive or negative roles in 
transformation, depending on their sequence and their context 
within signal transduction pathways. For example, in the c-Abl 
and c-Src proteins, SH3 domains are inhibitory for cellular 
transformation [32-34], while SH3 adapter domains are re- 
quired for Crk mediated mitogenesis [35]. Our data suggest that 
the SH3 domain within the Z-region of PLC- y is responsible 
for the mitogenic activity of microinjected PLC-y (Table 1). 
While an SH 3 domain is necessary for induction of mitogenesis 
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Fig. 3. Microinjection of PLC-~'I Z-protein domains into quiescent 3T3 fibroblasts. BrdU incorporation i to the nucleus was determined by 
immunostaining as described in section 2. Frames (a-c): Z-protein injections; a, 240 ktg/ml; b, 120 ¢tg/ml; c, 60 ¢tg/ml. Frames (d f): Z(SH2-/-) 
injections; d, 200 ~g/ml; e, 100 ,ug/ml; f, 50 ,ug/ml. Frames (g,h): Z (SH3-) injections: g,574 ¢tg/ml; h, 120 ¢tg/ml. 
in this assay, it is not sufficient, as the GST-PLC-y SH3 fusion 
protein is unable to induce mitogenesis. We are currently inves- 
tigating what other sequences in the Z-peptides are required for 
mitogenic activity. 
The PLC-~' Z-region protein also appears to function differ- 
ently from the adapter proteins, Grb2 and Grb3. Grb2 is not 
mitogenic by microinjection unless it is co-injected with excess 
Ras protein [25]. The SH3 domain of Grb3, which is 90% 
conserved relative to Grb2, has been reported to induce apop- 
tosis when microinjected into serum starved Swiss 3T3 cells 
[36]. The differences in biological activities between these SH3- 
domain proteins might be explained by their sequence differ- 
ences. The SH3 domains of Grb2/3 and PLC-y have distinct 
binding preferences: e.g. PLC-y SH3 binds readily to the P2 
dynamin peptide while the Grb2 SH3 does not [13]. Most dra- 
matically, the different SH3 domains can be found in different 
parts of the cell following microinjection: GST fusions with 
Grb2-SH3 are found in the membrane ruffles following micro- 
injection, while GST-PLC-y SH3 fusion proteins can be local- 
ized to the actin cytoskeleton [37]. Thus, the disparity in their 
activities might be explained by their differential avidities for 
particular binding partners in the cell. 
We propose that the high level of overexpression (as deter- 
mined by injection volumes and immunostaining) achieved by 
microinjection of these proteins reveals a critical interaction 
between PLC-y's SH3 domain and essential components of the 
cellular mitogenic apparatus. Our data do not indicate whether 
PLC-y's SH3 domain induces mitogenesis by activating a cellu- 
lar mitosis-inducing factor or by inhibiting a cellular mitosis- 
inhibiting protein. Potential candidates for these activities, cel- 
lular SH3-binding proteins, have been identified (e.g. 
[13,38,39]). The specific proteins which bind to PLC-y Z-pro- 
teins under physiological concentrations, and the relevance of 
these interactions to the biological activity of PLC-y, is cur- 
rently under investigation. 
After the completion of the current study, a report was pub- 
lished which also demonstrates that the catalytic activity of 
PLC is not required for mitogenesis [40]. The results described 
in that report substantively concur with our results using the 
catalytic site mutant of PLC-y  and also demonstrates that the 
catalytic activity of PLC is not required for mitogenesis*. 
*The results described inSmith et al. [40] confirm that the H335 active 
site mutant was still mitogenic when microinjected into quiescent fi-
broblasts. These authors report hat their mutant isonly partially active 
in the mitogenesis a say, however, and that full activity could be re- 
stored by co-injections ofmutant protein with the enzymatic products, 
IP 3 and DAG. The differences between our observations and those of 
Smith et al. might be explained by different sources of the recombinant 
enzymes: our protein was obtained from E. coli and was therefore 
unphosphorylated, while Smith et al. obtained their protein from a 
mammalian cell expression system. Thus, differential post-translational 
processing might account for the different relative mitogenic activities 
of the wild type and mutant enzymes when microinjected into cells. We 
are in accord with regard to their fundamental conclusion, however: 
that a catalytically inactive mutant of PLC-y retains ubstantial mito- 
genic activity. In the current study, we have mapped this activity to the 
SH3 domain. 
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